Volume 2, Issue 1, March 2023

					View Volume 2, Issue 1, March 2023
  • Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada
  • Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma
  • Management of limited stage Hodgkin lymphoma
  • Tyrosine kinase inhibitors for the frontline management of CML: An overview
  • Venetoclax-based lower-intensity regimens for acute myeloid leukemia: Clinical pearls for a new standard of care
Published: 2023-03-01